Presentations and Posters
Innovation of the first-line strategy optimized as abemaciclib with endocrine therapy based on the ESR1 mutation of ctDNA for patients with HR-positive HER2-negative advanced metastatic breast cancer (JBCRG-M08; AMBER study).
Tetsuhiro Yoshinami, Shinsuke Sasada, Meiko Nishimura, Madoka Iwase, Chiya Oshiro, Kaori Terata, Mikiya Ishihara, Hiroko Bando, Masahiko Tanabe, Nobuyasu Yoshimoto, Sayuri Akiyoshi, Masahiro Takada, Hiroshi Ishiguro, Shigehira Saji, Satoshi Morita, Norikazu Masuda
ASCO, 2024 June, Chicago, USA（Poster）
Identification of Prognostic and Predictive Biomarkers for Palbociclib Add-On Therapy using Cancer Panel Sequencing of Cell-Free DNA in Patients with HR-Positive/HER2-Negative Advanced and Metastatic Breast Cancer with Fulvestrant Resistance
Takashi Takeshita, Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Hiroshi Tada, Shinji Ozaki, Toshitaka Okuno, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
AACR, 2024 Apr, San Diego, USA（Poster）
Health-Related QOL and Physical Activity Collected via Wearable Device in Patients With HR+/HER2–Advanced Breast Cancer in Japan. Treated With Palbociclib+Endocrine Therapy (ET) or ET Alone: 6-Month Longitudinal Study (JBCRG-26)
Hiroko Bando, Mari Oba, Aya Ueda, Kaori Terata, Mihoko Doi, Shigenori Nagai, Masaya Hattori, Kenichi Watanabe, Nobuko Tamura, Manabu Futamura, Kei Koizumi, Naoki Niikura, Tempei Miyaji, Yasuaki Muramatsu, Linghua Xu, Norikazu Masuda, Shigehira Saji
San Antonio Breast Cancer Symposium, 2023 Dec, Texas USA (Poster)
Patients with HR-positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
Hatem A Azim J, Samuel M Niman, Ann H Partridge, Isabelle Demeestere, Monica Ruggeri, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B. Saetersdal, Judith R. Kroep, Audrey Mailliez, Ellen Warner, Virginia F Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E Lee, Janice M. Walshe, Manuel Ruíz-Borrego, Halle C F Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, N. J. Klar, Tanja. Spanic, Kathryn Ruddy, Martine Piccart, Larissa A Korde, Aron Goldhirsch †, Richard D Gelber, Olivia Pagani, Fedro A Peccatori
San Antonio Breast Cancer Symposium, 2023 Dec, Texas USA (Oral)
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Takashi Takeshita, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Hiroshi Tada, Shinji Ozaki, Toshitaka Okuno, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
ESMO, 2023 Oct, Madrid Spain (ポスター)
Pertuzumab retreatment in patients with HER2-positive locally advanced/ metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS).
Yutaka Yamamoto, Hiroji Iwata, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Naruto Taira, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno, Norikazu Masuda
ASCO, 2023 Jun, Chigago USA (Poster Discussion Session)
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
Kenichi Inoue, Norikazu Masuda, Toshimi Takano, Mitsuya Ito, Yuko Tanabe, Kosuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R. Kataoka, Satoshi Morita, Masakazu Toi
ESMO Breast Cancer, 2023 May, Berlin Germany (Mini Oral)
Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer Initial Results from the POSITIVE Trial
Ann H Partridge, Samuel M Niman, Monica Ruggeri, Fedro A Peccatori, Hatem A Azim Jr, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B Sætersdal, Judith R Kroep, Audrey Mailliez, Ellen Warner, Virginia F Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E Lee, Janice M Walshe, Manuel Ruíz-Borrego, Halle C F Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Karen L Smith, Teresa Ferreiro, Karin Ribi, Kathryn Ruddy, Sarra El-Abed, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani
SABCS, 2022 Dec, Texas USA (Oral)
Retrospective study using database for the effectiveness of medroxyprogesterone acetate in patients with ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study
Kaho Utsunomiya, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi and Shinji Ohno
2022.12 SABCS Poster San Antonio, Texas
Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)
Kenichi Watanabe, Naoki Niikura, Yuichiro Kikawa, Mari Oba, Kokoro Kobayashi, Hiroshi Tada, Shinji Ozaki, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Toshitaka Okuno, Nobutaka Iwakuma, Takeshi Takeshita, Takayuki Iwamoto, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
2022.9 ESMO Poster WEB
by Voluntary Organization JBCRG